IL-1β is known to be expressed in TIMs and has been studied in NSCLC (30); however, recent clinical trials using an IL-1β targeting antibody (Canakinumab) failed to show improved NSCLC outcomes (31–35). The gene discussed is IL1B; the disease is non-small cell lung carcinoma.